S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

Trevena Stock Forecast, Price & News

-0.03 (-5.88%)
(As of 01/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.34 million shs
Average Volume
781,176 shs
Market Capitalization
$78.97 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Trevena logo

About Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.


Trevena (TRVN) to Begin Clinical Study on Pain Candidate
December 14, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.07 million
Book Value
$0.66 per share


Net Income
$-29.37 million
Net Margins
Pretax Margin




Free Float
Market Cap
$78.97 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.78 out of 5 stars

Medical Sector

872nd out of 1,417 stocks

Pharmaceutical Preparations Industry

428th out of 683 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena
or view top-rated stocks.

How has Trevena's stock been impacted by Coronavirus (COVID-19)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRVN stock has decreased by 31.3% and is now trading at $0.48.
View which stocks have been most impacted by COVID-19

Are investors shorting Trevena?

Trevena saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 5,600,000 shares, a decrease of 22.5% from the December 31st total of 7,230,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is presently 3.8 days. Approximately 3.6% of the shares of the stock are short sold.
View Trevena's Short Interest

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Trevena

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $0.18 million during the quarter, compared to analysts' expectations of $1.16 million. Trevena had a negative net margin of 7,771.74% and a negative trailing twelve-month return on equity of 53.47%. During the same quarter in the previous year, the firm earned ($0.04) EPS.
View Trevena's earnings history

What price target have analysts set for TRVN?

2 Wall Street analysts have issued 1-year target prices for Trevena's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts' price targets for Trevena
or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Carrie L. Bourdow, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Barry Shin, Chief Financial Officer & Senior Vice President
  • Mark A. Demitrack, Chief Medical Officer & Senior Vice President
  • Angela Bagley, Vice President-Technical Operations
  • Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

What other stocks do shareholders of Trevena own?

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.48.

How much money does Trevena make?

Trevena has a market capitalization of $78.97 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29.37 million in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.